PRESCINTO-TECHNOLOGIES
22.11.2022 07:01:42 CET | Business Wire | Press release
Prescinto Technologies (“Prescinto”), a leading global clean energy asset performance management (APM) SaaS platform, and SunSolarWind IKE (“SunSolarWind”), a Thessaloniki-based wind and solar energy project developer with a rapidly growing portfolio of more than 100 projects across Greece, today announced a partnership in which Prescinto will apply its world-class AI-powered APM solution to monitor, analyze, optimize the performance of 70 MW of SunSolarWind’s solar assets. This alliance will streamline operations and maintenance for SunSolarWind and improve their solar asset generation by providing accurate, real-time data and actionable insights. The deal also marks Prescinto’s entry into the European market following the announcement of its recent entry into the North American market.
As one of the fastest-growing companies in Greece, SunSolarWind is a leader in renewable energy development and provides complete packages for the construction and management of wind and photovoltaic energy projects on behalf of its customers and partners. Using Prescinto’s proprietary AI-powered software, the company will have access to advanced monitoring technology and pre-trained data models to identify and categorize underperformance in real time. The platform will provide a single point of verification for SunSolarWind’s solar plant data, extracting up-to-the-minute insights and efficiently managing the field service team’s daily operations using Prescinto’s Monitor, Analyze, and Operate product modules. These solutions leverage data-driven intelligence to enable informed asset management and maximize the value of SunSolarWind clean energy assets.
In an increasingly competitive energy market, digital technology plays a critical role in optimizing operations and performance. SunSolarWind chose Prescinto as their digital transformation partner after a stringent evaluation of multiple other solutions. Additionally, Prescinto’s APM software is uniquely designed to efficiently adapt to the client's needs and is tailored to SunSolarWind’s specific requirements.
“Our team has worked closely with SunSolarWind to understand their bottlenecks and implement the appropriate solutions to enhance energy generation and streamline their operations,” said Puneet Singh Jaggi, founder and CEO of Prescinto. “As our first of many major partnerships to come in the European market, we are excited to be a part of SunSolarWind’s digital transformation journey and help them harness the full potential of their clean energy assets.”
“With our exponential growth in managed assets, the SunSolarWind team can now focus more on improving asset performance with a considerable reduction in time and effort,” says Konstantinos Fountas, Partner at SunSolarWind. “The advanced analytics in Prescinto’s platform helps to identify and plan remedial action and reduce equipment downtimes. For a company like ours, Prescinto’s solution, and their Computerized Maintenance Management System in particular, is a boon.”
With its expansion into the European market with its first Greece-based client, Prescinto is poised for further growth and progress toward its goal of being the asset management platform of choice for renewable energy projects, globally.
About Prescinto Technologies
Prescinto Technologies is a leading global clean energy asset performance management SaaS platform for solar, wind, and energy storage, purpose-built by industry experts to improve asset generation and accelerate the clean energy transition. Prescinto provides real-time insights, analytics, and automation support for optimizing renewable energy asset performance. With a veteran team of industry experts and a portfolio of over 13 GW across 14 countries, Prescinto is the trusted partner for global clients working toward the clean energy transition. For more info, visit www.prescinto.ai.
About SunSolarWind
Sun Solar Wind Ike is a rapidly growing company in the field of environmental energy applications, comprised of well-trained and certified staff. The company offers complete packages for the construction and management of photovoltaic systems and energy projects on behalf of either its customers or its partners – installers. With more than 70MWp of assets under management in Greece, SunSolarWind is among Greece's fastest-growing renewable energy companies. For more info, visit www.sunsolarwind.gr.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom